- BreathID Hp
- Events & Webinars
- Patient Information
Exalenz provides hepatologists, gastroenterologists, bariatric surgeons, urgent care centers, and primary care physicians with advanced tools for the diagnosis and management of a wide range of conditions in the field of liver health and gastroenterology.
The BreathID technology platform is an advanced, continuous, automatic and real-time breath-testing platform that enables the detection of the presence of the Helicobacter pylori bacteria, assessment of liver function across a range of clinical conditions, gastric emptying.
The company's stock is traded on the Tel Aviv Stock Exchange (TASE) in Israel. Its ticker symbol is EXEN.
In the U.S. the BreathID System is FDA-cleared for use in the qualitative detection of H. pylori. Outside the U.S., the BreathID technology platform and associated testing kits have CE mark for assessing Helicobacter pylori, Liver Function and Gastric Emptying Rate in the European Union and is approved for the same uses in Israel.